P/E ratio for AngioDynamics (ANGO)
P/E ratio as of May 2023 (TTM): -9.86
According to AngioDynamics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -9.85638. At the end of 2021 the company had a P/E ratio of -27.9.
P/E ratio history for AngioDynamics from 2004 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -27.9 | 712.31% |
| 2020 | -3.43 | -131.92% |
| 2019 | 10.7 | -73.84% |
| 2018 | 41.1 | -152.11% |
| 2017 | -78.8 | 264.5% |
| 2016 | -21.6 | -69.71% |
| 2015 | -71.4 | -167.62% |
| 2014 | 106 | -138.66% |
| 2013 | -273 | 645.69% |
| 2012 | -36.6 | -164.31% |
| 2011 | 57.0 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 31.9 | -423.44% | 🇺🇸 USA |
 Boston Scientific BSX | 86.6 | -978.72% | 🇺🇸 USA |
 Teleflex TFX | 30.1 | -405.25% | 🇺🇸 USA |
 Merit Medical MMSI | 55.0 | -658.01% | 🇺🇸 USA |
 LeMaitre Vascular LMAT | 63.9 | -748.25% | 🇺🇸 USA |
 ICU Medical
ICUI | -90.1 | 814.54% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.